Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Soligenix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Soligenix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Soligenix Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Soligenix Acquires SGX301 from Hy Biopharma for USD14 Million 12
Soligenix Acquires SGX94 from Inimex Pharma 14
Venture Financing 15
Soligenix Raises USD2 Million in Venture Financing 15
Partnerships 16
Soligenix Enters into Co-Development Agreement with University of Hawaii at Manoa and Hawaii Biotech 16
Soligenix Expands its Development Agreement with Emergent BioSolutions 17
Soligenix Enters into Contract with National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority 18
Soligenix Enters Into Co-Marketing Agreement With SciClone Pharma For SGX942 19
Soligenix Enters Into Co-Development Agreement With Intrexon 20
Soligenix Enters Into Agreement With Infectious Disease Research Institute To Develop Biodefense Vaccines 21
Licensing Agreements 23
SciClone Pharma Enters into Licensing Agreement with Soligenix 23
Soligenix Enters into Licensing Agreement with New York University and Yeda Research and Development 24
Soligenix Enters Into Licensing Agreement With Intrexon To Develop Melioidosis Therapy 25
Equity Offering 27
Soligenix to Raise up to USD9 Million in Public Offering of Shares 27
Soligenix Raises USD8 Million in Public Offering of Shares and Warrants 28
Soligenix Plans to Raise up to USD2.16 Million in Private Placement of Shares 30
Soligenix Raises USD3.2 Million in Public Offering of Shares 31
Soligenix Raises USD2 Million in Private Placement of Shares 32
Soligenix Raises USD5.3 Million in Public Offering of Shares and Warrants 33
Soligenix to Raise USD12 Million in Private Placement of Shares 35
Soligenix Raises USD2.3 Million in Public Offering of Shares 36
Soligenix Completes First Tranche Of Private Placement Of Shares For US$0.6 Million 38
Soligenix Completes Private Placement Of Units For US$7 Million 39
Soligenix Inc – Key Competitors 40
Soligenix Inc – Key Employees 41
Soligenix Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Aug 08, 2018: Soligenix announces recent accomplishments and second quarter 2018 financial results 43
May 11, 2018: Soligenix Announces Recent Accomplishments And First Quarter 2018 Financial Results 44
Mar 15, 2018: Soligenix Announces Recent Accomplishments And Year-End 2017 Financial Results 45
Nov 06, 2017: Soligenix Announces Recent Accomplishments And Third Quarter 2017 Financial Results 46
Aug 11, 2017: Soligenix Announces Recent Accomplishments And Second Quarter 2017 Financial Results 47
May 11, 2017: Soligenix Announces Recent Accomplishments And First Quarter 2017 Financial Results 49
Mar 27, 2017: Soligenix Announces Recent Accomplishments And Year-End 2016 Financial Results 51
Corporate Communications 53
Jul 24, 2018: Soligenix announces appointment of mark pearson to its board of directors 53
Government and Public Interest 54
Jul 19, 2018: Soligenix driving towards key inflection points with two pivotal phase 3 clinical trials 54
Product Approvals 56
Feb 02, 2017: Soligenix Announces SGX301 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency 56
Jan 05, 2017: Soligenix Receives Positive Scientific Advice from the European Medicines Agency for SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer Patients 57
Clinical Trials 58
Jun 04, 2018: Soligenix Announces Poster at the 2018 American Society of Microbiology Microbe Conference in Atlanta, Georgia 58
Jan 02, 2018: Soligenix Announces US Patent Issuance for Use of Dusquetide in Oral Mucositis 60
Nov 27, 2017: Soligenix Announces Presentation of Data on Dusquetide at Chemical and Biological Defense Science and Technology Conference 62
Oct 24, 2017: Broad-Spectrum Innate Defense Regulator Platform Technology to be Presented at the Peptide Therapeutics Foundation Symposium 63
Oct 05, 2017: Dusquetide Technology Platform to be Presented at the 2nd World Congress and Expo on Immunology 65
Jul 27, 2017: Soligenix Initiates Pivotal Phase 3 Clinical Trial of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 67
Jun 19, 2017: Complete Efficacy and Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial to be Presented at the 2017 Multinational Association for Supportive Care in Cancer Conference 69
May 18, 2017: Soligenix Announces Publication Of Its Phase 2 Long-term Follow-up Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 71
May 03, 2017: Soligenix Receives FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 73
Other Significant Developments 74
Jan 25, 2018: Soligenix – Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials 74
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77
Soligenix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Soligenix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Soligenix Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Soligenix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Soligenix Acquires SGX301 from Hy Biopharma for USD14 Million 12
Soligenix Acquires SGX94 from Inimex Pharma 14
Soligenix Raises USD2 Million in Venture Financing 15
Soligenix Enters into Co-Development Agreement with University of Hawaii at Manoa and Hawaii Biotech 16
Soligenix Expands its Development Agreement with Emergent BioSolutions 17
Soligenix Enters into Contract with National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority 18
Soligenix Enters Into Co-Marketing Agreement With SciClone Pharma For SGX942 19
Soligenix Enters Into Co-Development Agreement With Intrexon 20
Soligenix Enters Into Agreement With Infectious Disease Research Institute To Develop Biodefense Vaccines 21
SciClone Pharma Enters into Licensing Agreement with Soligenix 23
Soligenix Enters into Licensing Agreement with New York University and Yeda Research and Development 24
Soligenix Enters Into Licensing Agreement With Intrexon To Develop Melioidosis Therapy 25
Soligenix to Raise up to USD9 Million in Public Offering of Shares 27
Soligenix Raises USD8 Million in Public Offering of Shares and Warrants 28
Soligenix Plans to Raise up to USD2.16 Million in Private Placement of Shares 30
Soligenix Raises USD3.2 Million in Public Offering of Shares 31
Soligenix Raises USD2 Million in Private Placement of Shares 32
Soligenix Raises USD5.3 Million in Public Offering of Shares and Warrants 33
Soligenix to Raise USD12 Million in Private Placement of Shares 35
Soligenix Raises USD2.3 Million in Public Offering of Shares 36
Soligenix Completes First Tranche Of Private Placement Of Shares For US$0.6 Million 38
Soligenix Completes Private Placement Of Units For US$7 Million 39
Soligenix Inc, Key Competitors 40
Soligenix Inc, Key Employees 41
Soligenix Inc, Subsidiaries 42
List of Figures
Soligenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Soligenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Soligenix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9